These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 27591097)

  • 1. Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.
    Sheffield BS; Fulton R; Kalloger SE; Milne K; Geller G; Jones M; Jacquemont C; Zachara S; Zhao E; Pleasance E; Laskin J; Jones SJ; Marra MA; Yip S; Nelson BH; Gown AM; Ho C; Ionescu DN
    J Histochem Cytochem; 2016 Oct; 64(10):587-600. PubMed ID: 27591097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
    McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
    JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [PD-L1 expression: An emerging biomarker in non-small cell lung cancer].
    Adam J; Planchard D; Marabelle A; Soria JC; Scoazec JY; Lantuéjoul S
    Ann Pathol; 2016 Jan; 36(1):94-102. PubMed ID: 26778219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
    Scheel AH; Dietel M; Heukamp LC; Jöhrens K; Kirchner T; Reu S; Rüschoff J; Schildhaus HU; Schirmacher P; Tiemann M; Warth A; Weichert W; Fischer RN; Wolf J; Büttner R
    Pathologe; 2016 Nov; 37(6):557-567. PubMed ID: 27510417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
    Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
    Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
    Kerr KM; Tsao MS; Nicholson AG; Yatabe Y; Wistuba II; Hirsch FR;
    J Thorac Oncol; 2015 Jul; 10(7):985-9. PubMed ID: 26134220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups.
    Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W
    PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
    Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
    Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer.
    Igawa S; Sato Y; Ryuge S; Ichinoe M; Katono K; Hiyoshi Y; Otani S; Nagashio R; Nakashima H; Katagiri M; Sasaki J; Murakumo Y; Satoh Y; Masuda N
    Oncology; 2017; 92(5):283-290. PubMed ID: 28222447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas.
    Coppock JD; Volaric AK; Mills AM; Gru AA
    Hum Pathol; 2018 Dec; 82():282-288. PubMed ID: 30075155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarkers for the Clinical Use of PD-1/PD-L1 Inhibitors in Non-Small-Cell Lung Cancer: A Review.
    Sacher AG; Gandhi L
    JAMA Oncol; 2016 Sep; 2(9):1217-22. PubMed ID: 27310809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Issues and current limits for immunohistochemical assessment of PD-L1 status in bronchial biopsies].
    Hofman V; Ilie M; Long E; Butori C; Lassalle S; Washetine K; Lalve S; Marquette CH; Soria JC; Hofman P
    Bull Cancer; 2016 Apr; 103(4):368-80. PubMed ID: 26920041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer.
    Phillips T; Simmons P; Inzunza HD; Cogswell J; Novotny J; Taylor C; Zhang X
    Appl Immunohistochem Mol Morphol; 2015 Sep; 23(8):541-9. PubMed ID: 26317305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.
    Ilie M; Hofman V; Dietel M; Soria JC; Hofman P
    Virchows Arch; 2016 May; 468(5):511-25. PubMed ID: 26915032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-Small Cell Lung Cancer, PD-L1, and the Pathologist.
    Kerr KM; Nicolson MC
    Arch Pathol Lab Med; 2016 Mar; 140(3):249-54. PubMed ID: 26927720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
    Calles A; Liao X; Sholl LM; Rodig SJ; Freeman GJ; Butaney M; Lydon C; Dahlberg SE; Hodi FS; Oxnard GR; Jackman DM; Jänne PA
    J Thorac Oncol; 2015 Dec; 10(12):1726-35. PubMed ID: 26473645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
    Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.
    Sholl LM; Aisner DL; Allen TC; Beasley MB; Borczuk AC; Cagle PT; Capelozzi V; Dacic S; Hariri L; Kerr KM; Lantuejoul S; Mino-Kenudson M; Raparia K; Rekhtman N; Roy-Chowdhuri S; Thunnissen E; Tsao MS; Yatabe Y;
    Arch Pathol Lab Med; 2016 Apr; 140(4):341-4. PubMed ID: 26780537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of
    Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
    Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer.
    Sheng J; Fang W; Yu J; Chen N; Zhan J; Ma Y; Yang Y; Huang Y; Zhao H; Zhang L
    Sci Rep; 2016 Jan; 6():20090. PubMed ID: 26822379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.